| Literature DB >> 18847522 |
Cristina Cunha Villar1, Anna Dongari-Bagtzoglou.
Abstract
The prevalence of oropharyngeal candidiasis continues to be high, mainly because of an increasing population of immunocompromised patients. Traditional treatment of oropharyngeal candidiasis has relied on the use of antimicrobial drugs. However, unsatisfactory results with drug monotherapy and the emergence of resistant strains have prompted investigations into the potential use of adjunctive immunoenhancing therapies for the treatment of these infections. Here we review the host-recognition systems of Candida albicans, the immune and inflammatory response to infection, and antifungal effector mechanisms. The potential of immune modulation as a therapeutic strategy in oropharyngeal candidiasis is also discussed.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18847522 PMCID: PMC2712880 DOI: 10.1017/S1462399408000835
Source DB: PubMed Journal: Expert Rev Mol Med ISSN: 1462-3994 Impact factor: 5.600